Abbott has introduced first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system designed to address tricuspid regurgitation, a condition where the tricuspid heart valve leaks, placing additional strain on the heart and potentially leading to further cardiovascular complications.
Currently, treatment options for this condition have been limited, leaving many individuals with compromised quality of life. However, TriClip offers a vital alternative for those unable to undergo traditional surgery.
The tricuspid valve plays a crucial role in regulating blood flow from the heart's right atrium to the right ventricle. Tricuspid regurgitation occurs when this valve fails to close properly, resulting in blood flowing backward within the heart.
For individuals experiencing persistent symptoms or ineffective response to medical therapy, and who are deemed unsuitable candidates for surgery, TriClip presents a promising solution to enhance quality of life.
Administered through a leg vein, TriClip's TEER technology facilitates the repair of the tricuspid valve by clipping together a portion of its leaflets, thus redirecting blood flow without necessitating open-heart surgery.
Tricuspid regurgitation can result in symptoms such as fatigue, shortness of breath, irregular heart rhythms, swelling, and organ dysfunction, progressively impeding daily functioning and compromising overall well-being.
TriClip has obtained approval for use in over 50 countries, including Europe and Canada, and has already benefited more than 10,000 individuals afflicted with tricuspid regurgitation.
